Intelligent Bio Solutions Reports 38% Revenue Growth and 778bps Gross Margin Expansion
INBS has more than doubled off its 52-week low of $1.52.
Summary
Intelligent Bio Solutions reported fiscal 2026 revenue of $4.2 million, up 38%, with gross margin expanding 778 basis points to 48.63%. The company's FDA 510(k) submission is on track for the second half of 2026.
Key Events · Earnings and Guidance · INBS
-
Record Revenue and Margin Expansion
Full-year revenue reached $4,215,175, up 38% year-over-year, while gross profit grew 64% to $2,049,994. Gross margin expanded 778 basis points to 48.63%.
-
Installed Base and Cartridge Growth
Reader installed base grew 22% to 1,886 units, and consumable cartridge sales grew 35% to 106,500 units, indicating deepening utilization among 502 active customers.
-
FDA 510(k) Submission Timeline
All clinical data collection is complete, and the FDA 510(k) submission is on track for the second half of calendar 2026, supporting planned U.S. market entry.
-
Going Concern and Net Loss
The company reported a net loss of $12.4 million and a going concern warning, but cash and cash equivalents increased to $3.99 million from $1.02 million year-over-year.
Analysis · INBS · Industrial Applications And Services
Record annual revenue of $4.2 million, up 38% year-over-year, came with gross margin expanding to 48.63% from 40.85%. The razor-razorblade model is scaling: reader installed base grew 22% to 1,886 units, and consumable cartridge sales grew 35% to 106,500 units, outpacing hardware growth and confirming deepening utilization. The FDA 510(k) submission remains on track for the second half of calendar 2026, a key catalyst for U.S. market entry. Against a going concern warning and a $12.4 million net loss, these operational improvements show the business is gaining traction, though profitability remains distant.
At the time of this filing, INBS was trading at $3.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $1.52 to $24.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.